| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 28.4MM | +74% |
| Gross Profit | 17.8MM | +82% |
| Cost Of Revenue | 10.5MM | +61% |
| Operating Income | -10.9MM | - |
| Operating Expenses | 28.7MM | - |
| Net Income | -4.1MM | +45% |
| G&A | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024. As a company that provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at cr
Q4 revenue of $28.4 million, increasing 44% year-over-yearQ4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periodsAcquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics company that significantly expands our footprint with consumers and patientsMeaningfully increased our DAAP footprint: 24 DAAP deals in 2023 compared to six deals in 2022 WALTHAM, Mass., April 16, 2024 (
Market Embraces Disruptive AI-Powered CapabilitiesWALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253. The Americas’ Fastest Growing Companies 2024 ra
If you’re looking for undervalued stocks, you don’t have to look far, despite the rally. The past year or so has been a wild rollercoaster ride for investors. While the major indexes kept chugging along to fresh highs, propelled by the ‘Magnificent 7,’ plenty of other stocks got left behind in the dust. It’s been a tale of two markets – the haves and the have-nots, if you will. But here’s the thing: Just because a stock has been stuck in the mud doesn’t mean it’s destined to stay there forever.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript March 28, 2024 OptimizeRx Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is […]
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter. OptimizeRx management will host the call, followed by a question-and-answer period. Details for t
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023. The Company is working to complete its year end close and audit processes by the filing deadline fo
Empowering healthcare providers to remove barriers to careWALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its collaboration with Walmart to support its Specialty Pharmacies of the Community (SPOCs) provider outreach initiative. OptimizeRx’s Dynamic Audience Activation Platform (DAAP